Sesja plakatowa - spis prac

VIII Zjazd Polskiego Towarzystwa Tyreologicznego
SESJA 1. CHOROBY TARCZYCY U DOROSŁYCH I U DZIECI
Moderatorzy: prof. dr hab. Artur Bossowski / prof. dr hab. Agata Bałdys-Waligórska
Lp. Tytuł pracy Autor prezentujący
1.01 Zastosowanie zjawiska autofluorescencji przytarczyc do śródoperacyjnej identyfikacji i ochrony podczas zabiegów resekcji tarczycy u dzieci. Dariusz Polnik
1.02 Neurological aspects of thyroid dysfunction Jerzy S. Tarach
1.03 Continuous intraoperative neuromonitoring in pediatric thyroid surgery Anna Taczanowska-Niemczuk
1.04 Practical guidance in the management of endocrine immune-related adverse events in cancer immunotherapy Agnieszka Zwolak
1.05 Radioactive iodine therapy (RAI) for Graves‘ disease (GD) in children up to 15 years old. Aleksandra Król
1.06 THYROID CANCER IN CHILDREN - 24 YEARS OF EXPERIENCE FROM ONE CENTER Magdalena Tarasińska
1.07 Analysis of miR-15a-5p, miR-126-3p and miR-142-5p levels in blood of children and adolescents with thyroid diseases Artur Bossowski
1.08 Postoperative histopathological findings in thyroid nodules classified as Bethesda III category in children Anna Taczanowska-Niemczuk
1.09 Effects of therapy on Th1, Th17, Th22 and Bregs in pediatric patients with Graves’ disease Karolina Stożek
1.10 Machine learning risk prediction for thyroid nodules malignancy Magdalena Kamińska
1.11 The Application of Ultrasound Elastography in Combination with Ultrasound-based Risk Stratification Systems in Diagnosis of Malignant Thyroid Nodules in Children and Adoles-cents—Retrospective Analysis of One Center Artur Bossowski
1.12 Thyrotoxic psychosis – a case report of acute psychosis related to autoimmune thyroiditis Monika Lenart-Lipińska
 
II Zjazd Polskiego Towarzystwa Endokrynologii Onkologicznej
SESJA 2. GUZY NEUROENDOKRYNNE I INNE RZADKIE NOWOTWORY GRUCZOŁÓW WYDZIELANIA WEWNĘTRZNEGO
Moderatorzy: dr hab. Agnieszka Gilis-Januszewska / dr n. med. Elżbieta Andrysiak-Mamos
Lp. Tytuł pracy Autor prezentujący
2.01 Well-differentiated gastroenteropancreatic G3 NET: clinical characteristics, treatment and outcomes - personalized approach. Marta Opalińska
2.02 Radioembolization of Neuroendocrine Neoplasms Liver Metastases: Efficacy and Early Toxicity Michal Gola
2.03 Pembrolizumab in advanced, inoperable or metastatic adrenocortical carcinoma after first line chemotherapy failure –  Medical Research Agency  project – right before recruiting. Agnieszka Kotecka-Blicharz
2.04 Clinical course of parathyroid carcinoma based on own experience Barbara Michalik
2.05 Own experience in the treatment of parathyroid cancer Barbara Michalik
2.06 Corrected SUVmax change as a prognostic factor of response to PRRT Marta Opalińska
2.07 How clear cell renal cell carcinoma imitated metastatic neuroendocrine neoplasm – case report. Igor Syrenicz
2.08 The role of immunohistochemical staining of appendiceal neuroendocrine neoplasms. Dariusz Starzyński
 
II Zjazd Polskiego Towarzystwa Endokrynologii Onkologicznej
SESJA 3 - WSPÓŁPRACA INTERDYSCYPLINARNA MIĘDZY ENDOKRYNOLOGAMI I ONKOLOGAMI
Moderatorzy: dr med. Joanna Januszkiewicz-Caulier / prof. dr hab. Krzysztof Sworczak
Lp. Tytuł pracy Autor prezentujący
3.01 From obesity to cancer - what do we know about pathomechanisms and what can we do with this knowledge? Agnieszka Zwolak
3.02 Causes of hypocalcemia in cancer patients. A rare case of severe sequestration hypocalcemia in a patient with metastatic breast cancer. Ewa Tywanek
3.03 Sleep quality correlates with various aspects of quality of life in pituitary adenoma patients Karol Sagan
3.04 Diagnostic dilemmas in patient with postmenopausal hyperandrogenization Elżbieta Sowińska-Przepiera
3.05 Adrenocortical carcinoma in the pregnancy Elżbieta Sowińska-Przepiera
3.06 Cancer immunotherapy-induced endocrinopathies: a single centre experience Iwona Pałyga
3.07 Results of long-term observation for late endocrine effects in childhood cancer survivors Joanna Smyczyńska
3.08 The association between thyroid malignancy and Hashimoto’s disease in a single institution Mateusz Bereza
3.09 Etomidate infusion in the management of severe hypercortisolemia in the course of ACTH-etopic production by small-cell lung carcinoma -  a case report Joanna Świrska
3.10 Severe hypokalemia due to secondary mineralocorticoid excess syndrome (MCES) following abiraterone therapy in a patient with prostate cancer. A case report. Marcin Lewicki
3.11 Targeted magnetic resonance of the ovaries in the diagnosis of severe hyperandrogenaemia in postmenopausal woman – a case report Magdalena Stasiak
3.12 The role of mitotane concentration monitoring in the treatment of adrenal carcinoma - experience from the Gliwice center Sylwia Szpak-Ulczok
 
VI Konferencja „Rak Tarczycy”
SESJA 4 - PATOGENEZA I KLINIKA RAKA TARCZYCY U DOROSŁYCH I U DZIECI
Moderatorzy: prof. dr hab. Dorota Pach / dr hab. Anna Kucharska
Lp. Tytuł pracy Autor prezentujący
4.01 Malignant Neoplasms of Thyroid - Own Experience Krzysztof Kaczka
4.02 Changes in clinical presentation of differentiated thyroid cancer in children in 40-year experience of Department of Nuclear Medicine and Oncological Endocrinology in Gliwice Aleksandra Kropińska
4.03 Radioiodine treatment after thyroid hormone withdrawal or rhTSH stimulation- a single centre retrospective study  in metastatic  differentited thyroid cancer  in pediatric patients Aleksandra Kropińska
4.04 Does Hashimoto’s affect the course of papillary thyroid cancer? Based on patients group with high incidence of HT in PTC. Andrzej Hellmann
4.05 Review of thyroid cancer patients admitted in a tertiary reference center in 2020 Magdalena Kołton
4.06 The influence of coexistence of Graves’ disease on staging and clinicopathological characteristic of patients with differentiated thyroid carcinoma Łukasz Nawacki
4.07 The influence of coexistence of Hashimoto thyroiditis (HT) on staging and clinicopathological characteristic of patients with differentiated thyroid carcinoma (DTC) Iwona Pałyga
4.08 Papillary carcinoma and thyrotoxicosis - “red flag” symptoms. The clinical study of two children. Anna Kucharska
4.09 Prevalence of thyroid cancer in children with Graves’ disease treated in the Department of Pediatric Endocrinology and Rheumatology in Poznan, Poland (2005-2018) Maciej Flader
4.10 Malignant neoplasms of the thyroid gland in children and adolescents treated surgically - 50 years of experience Jerzy Harasymczuk
4.11 Effect of concentration  leptin and insulin on clinicopathological characteristic of differentiated thyroid cancer (DTC) - analysis of 675 cases. Estera Mikina
4.12 GLP-1 receptor agonists  and a risk of thyroid cancer-  a review of current knowledge Olga Wajtryt
4.13 Otyłość jako potencjalny czynnik ryzyka raka tarczycy – badanie wstępne Ewa Kiszczak-Bochyńska
 
VI Konferencja „Rak Tarczycy”
SESJA 5 - DIAGNOSTYKA PRZED- I POOPERACYJNA RAKA TARCZYCY
Moderatorzy: Prof. dr hab. Marek Dedecjus / Prof. dr hab. Janusz Dzięcioł
Lp. Tytuł pracy Autor prezentujący
5.01 Collision tumours of the thyroid – experience of a referral centre Patrycja Sordoń
5.02 Association of preoperative serum TSH level with thyroid cancer in patients with AUS/FLUS thyroid tumor diagnosis. Krzysztof Kaliszewski
5.03 Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 3879 patients. Agnieszka Suligowska
5.04 Does it correct to approach NIFTP as a variant characterized by noninvasive features? Kinga Hińcza-Nowak
5.05 The risk of malignancy in Bethesda IV thyroid nodules in Poland is low - time to slow down the rush to surgery Piotr Wiśniewski
5.06 Core needle biopsy of the thyroid- diagnostic rescue or unnecessary risk? Elwira Bakuła-Zalewska
5.07 Microcarcinoma of thyroid gland in patients with FNAB verified as follicular lesion of undetermined significance. Jarosław Świrta
5.08 The Thyroid Bethesda – ten years’ experience Juliusz Pankowski
5.09 Neck ultrasonography in the estimation of treatment effectiveness and in monitoring of thyroid cancer patients in the era of EBM. Joanna Januszkiewicz-Caulier
5.10 Clinical diagnostic value of contrast-enhanced ultrasound (CEUS) in differential diagnosis of thyroid nodules – own experience Agnieszka Żyłka
5.11 The prevalence of the cytological category in the Polish population according to Bethesda in a material from ultrasound guided fine-needle aspiration biopsy of the thyroid gland (FNAB) with preliminary material evaluation using an LED lamp Dariusz Lange
5.12 EU-TIRADS Classification for the differential diagnosis of Bethesda Category IV Agnieszka Żyłka
5.13 Paucicellular smears – does it always mean non diagnostic? Juliusz Pankowski
5.14 Papillary thyroid cancer- T1 and nodal metastases in the results of histopathological examinations. Lech Pomorski
5.15 Thyroid tumors of uncertain malignant potential according to WHO classification. Ewa Zembala-Nożyńska
 
VI Konferencja „Rak Tarczycy”
SESJA 6 - DIAGNOSTYKA MOLEKULARNA W RAKU TARCZYCY
Moderatorzy: prof. dr hab. Katarzyna Łącka / dr hab. n. med. Małgorzata Oczko-Wojciechowska
Lp. Tytuł pracy Autor prezentujący
6.01 Znaczenie profilu ekspresji miRNA w diagnostyce raka brodawkowatego tarczycy Mariusz Rogucki
6.02 Familial non-medullary thyroid cancer (FNMTC) - does the number of alanine residues in the FOXE1 gene matter? Bartosz Domagała
6.03 The presence of concomitant BRAFV600E and TERT mutations do not affect the clinical outcome of papillary thyroid microcarcinoma Artur Kuchareczko
6.04 FRMD5: a new player in molecular biology of papillary thyroid carcinoma Agata M. Gaweł
6.05 hMTH1 protein interactome revealed using BioID method in normal SV40-transformed thyroid cells. Katarzyna Arczewska
6.06 Analysis of the role of the HMGB1 in papillary carcinoma cells. Małgorzata Grzanka
6.07 Elucidation of the role of podoplanin in papillary carcinoma using NGS-based assay Ewa Gajda
6.08 Polymorphisms associated with Thyroid-Stimulating Hormone levels predispose to Papillary Thyroid Carcinoma Jarosław Jendrzejewski
6.09 Prevalence of thyroid cancer in patients with multinodular goiter and DICER1 pathogenic variant Marek Niedziela
6.10 TGF β and differentiated thyroid cancer Adam Bednarczyk
6.11 The behavior of TGF β in patients operated on for  nodular goiter, and obesity. Adam Bednarczyk
6.12 A rapid course of papillary thyroid carcinoma in patients with genetic susceptibility Magdalena Stasiak
 
VI Konferencja „Rak Tarczycy”
SESJA 7 - OPERACJE W RAKU TARCZYCY I TECHNIKI ALTERNATYWNE LECZENIA MIEJSCOWEGO
Moderatorzy: prof. dr hab. Lech Pomorski / dr med. Zbigniew Wygoda
Lp. Tytuł pracy Autor prezentujący
7.01 Ultrasound-guided laser ablation of euthyroid benign thyroid nodules: preliminary results at six months in 144 patients Marcin Barczyński
7.02 A randomized controlled trial comparing near infrared autofluorescence technology with visual identification of parathyroid glands in the prevention of postoperative hypoparathyroidism: an interim safety analysis of a single recruiting center in a multicenter study Marcin Barczyński
7.03 Radioguided occult lesion localization (ROLL) technique in patients with thyroid cancer relapse. Grzegorz Woźniak
7.04 Stereotactic radiotherapy for thyroid cancer – When the surgeon can’t help. Aleksandra Kukulska
7.05 Lobectomy for the treatment of thyroid cancer -  outcomes of implementation of the 2018 Polish consensus in a single center. Maciej Śledziński
7.06 Thyroid lobectomy as a diagnostic and therapeutic procedure – critical analysis of five hundred operations Piotr Góralski
7.07 Transcervical Extended Mediastinal Lymphadenectomy in lymph node metastses of thyroid cancer - a single institution experience. Jarosław Świrta
 
VI Konferencja „Rak Tarczycy”
SESJA 8 - LECZENIE ZAAWANSOWANEGO RAKA TARCZYCY – RADIOJOD I FARMAKOTERAPIA UKIERUNKOWANA NA CELE MOLEKULARNE. PROBLEMY ZWIĄZANE Z LECZENIEM RAKA RDZENIASTEGO TARCZYCY.
Moderatorzy: dr hab. Jolanta Krajewska / dr hab. Rafał Czepczyński
Lp. Tytuł pracy Autor prezentujący
8.01 Prospective, observational study on radioiodine treatment in DTC patients with intermediate risk or micro lymph node metastases Aleksandra Blewązka
8.02 The intensity of the oxidative stress measurements in patients with differentiated thyroid cancer undergoing radioiodine therapy Angelika Buczyńska
8.03 CD276 as important candidate for immunotherapy in medullary thyroid cancer Kinga Hińcza-Nowak
8.04 Specification of psychological functioning of patients taking part in clinical research on new medications in advanced thyroid cancer therapy. Anna Syska-Bielak
8.05 Is there genetic predisposition for medullary thyroid cancer in RET Y791T variant carriers? Magdalena Kołton
8.06 Neurological rehabilitation as an integral part of the therapeutic process of patients with thyroid cancer Sylwia Jezierska
8.07 Unexpected 131-I iodine scintigraphy finding Aleksandra Aulich
8.08 Vandetanib in real-life practice – a retrospective evaluation of the Polish cohort Jolanta Krajewska
8.09 Metastatic differentiated thyroid cancer – effectiveness of radioiodine treatment after recombinant human TSH (rhTSH) stimulation Ewa Paliczka-Cieślik
8.10 Grading systems of medullary thyroid carcinoma in hereditary and sporadic tumors. Ewa Chmielik
8.11 Dosimetric evaluation of I-131 treatment in patients with differentiated thyroid carcinoma - standardization of the data collection method Aneta Kluczewska-Gałka
 
VI Konferencja „Rak Tarczycy”
SESJA 9 - KAZUISTYKA RAKA TARCZYCY
Moderatorzy: dr Aleksandra Kropińska / dr Iwona Pałyga
Lp. Tytuł pracy Autor prezentujący
9.01 Metastasis of breast cancer to the thyroid gland 20 years after a diagnosis of the primary disease – a case report Agnieszka Florczak
9.02 Thyroid-type carcinoma in ovarian teratoma: a challenge for researchers and clinicians  - report of five cases Paulina Godlewska
9.03 Follicular thyroid carcinoma in the struma ovarii : a case report. Tomasz Trybek
9.04 Papillary thyroid cancer (PTC) 18 years after treatment with Large B- cell lymphoma (LBCL) -a case report Estera Mikina
9.05 Neoadjuvant treatment with radioactive iodine (131I) of a patient with inoperable papillary thyroid cancer (PTC) and distant metastases- a case report. Aleksander Toś
9.06 Benign metastasizing leiomyoma in patient with oncological history – case report Anna Brzeska
     

 

Sponsor Diamentowy


Sponsor Platynowy

Sponsor Złoty